RELMADA THERAPEUTICS, INC. - Common Stock ($.001 par value) (RLMD) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2019 to Q4 2025

Type / Class
Equity / Common Stock ($.001 par value)
Symbol
RLMD on Nasdaq
Shares outstanding
74,702,121
Price per share
$3.95
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
50,901,642
Total reported value
$245,749,015
% of total 13F portfolios
0%
Share change
+32,232,730
Value change
+$155,594,526
Number of holders
77
Price from insider filings
$3.95
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of RELMADA THERAPEUTICS, INC. - Common Stock ($.001 par value) (RLMD) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
JANUS HENDERSON GROUP PLC 10% $35,932,374 7,439,415 JANUS HENDERSON GROUP PLC 30 Jan 2026
Squadron Capital Management LLC 9.9% 0% $31,283,007 +$17,330,352 7,395,510 +124% Squadron Master Fund LP 31 Dec 2025
Adage Capital Management, L.P. 5.8% $18,062,100 4,270,000 Adage Capital Management, L.P. 31 Dec 2025
Spruce Street Capital LP 5.6% $17,284,546 4,086,181 Spruce Street Capital LP 31 Dec 2025
Ikarian Capital, LLC 4.8% $7,122,152 3,543,359 Ikarian Capital, LLC 30 Sep 2025

As of 31 Dec 2025, 77 institutional investors reported holding 50,901,642 shares of RELMADA THERAPEUTICS, INC. - Common Stock ($.001 par value) (RLMD). This represents 68% of the company’s total 74,702,121 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of RELMADA THERAPEUTICS, INC. - Common Stock ($.001 par value) (RLMD) together control 63% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
JANUS HENDERSON GROUP PLC 9.7% 7,270,000 0.02% $35,041,400
Squadron Capital Management LLC 9% 6,700,000 0% 14% $32,361,000
ADAGE CAPITAL PARTNERS GP, L.L.C. 5.7% 4,270,000 0.03% $20,624,100
Spruce Street Capital LP 5.5% 4,086,181 0% 6.5% $19,736,254
MARSHALL WACE, LLP 4.3% 3,189,662 +1072% 0.01% $15,406,068
Ikarian Capital, LLC 4.1% 3,068,359 +66% 1.9% $14,820,175
ORBIMED ADVISORS LLC 3.5% 2,610,600 0.27% $12,609,198
AMERIPRISE FINANCIAL INC 2.6% 1,920,099 0% $9,274,078
Driehaus Capital Management LLC 2.5% 1,880,006 +154% 0.06% $9,080,429
MILLENNIUM MANAGEMENT LLC 2.2% 1,673,017 0.01% $8,080,672
BRAIDWELL LP 2.1% 1,582,257 0.24% $7,642,301
BlackRock, Inc. 1.7% 1,267,503 +150% 0% $6,122,039
VANGUARD GROUP INC 1.6% 1,203,307 +187% 0% $5,811,973
Opaleye Management Inc. 1.3% 935,000 0.6% $4,516,050
GEODE CAPITAL MANAGEMENT, LLC 1.1% 854,932 +189% 0% $4,131,406
BOOTHBAY FUND MANAGEMENT, LLC 1.1% 835,300 +20% 0.11% $4,034,499
Corient Private Wealth LLC 0.96% 719,582 +248% 0.01% $3,443,379
TWO SIGMA INVESTMENTS, LP 0.77% 572,835 +230% 0% $2,766,793
Balyasny Asset Management L.P. 0.73% 547,854 0% $2,646,135
ACADIAN ASSET MANAGEMENT LLC 0.71% 526,718 -9.6% 0% $2,541,000
DIADEMA PARTNERS LP 0.52% 389,395 1.1% $1,880,778
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.52% 385,942 +179% 0% $1,864,100
STATE STREET CORP 0.43% 320,820 +215% 0% $1,549,561
AdvisorShares Investments LLC 0.43% 319,510 -21% 0.26% $1,543,233
JANE STREET GROUP, LLC 0.36% 271,109 +216% 0% $1,309,456

Institutional Holders of RELMADA THERAPEUTICS, INC. - Common Stock ($.001 par value) (RLMD) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 50,901,642 $245,749,015 +$155,594,526 $4.83 77
2025 Q3 7,739,580 $15,541,689 +$5,268,375 $2.01 43
2025 Q2 5,303,151 $3,177,608 -$311,761 $0.60 48
2025 Q1 6,219,491 $1,678,348 -$765,348 $0.27 43
2024 Q4 8,399,225 $4,362,564 -$9,886,723 $0.52 48
2024 Q3 12,376,687 $40,240,571 -$3,630,516 $3.24 69
2024 Q2 13,555,167 $40,671,232 -$3,047,999 $3.00 78
2024 Q1 14,295,630 $66,487,069 +$3,440,282 $4.65 90
2023 Q4 13,621,440 $56,386,775 -$3,313,848 $4.14 83
2023 Q3 14,992,668 $44,979,292 -$3,168,578 $3.00 87
2023 Q2 16,099,667 $39,628,526 -$4,052,287 $2.46 91
2023 Q1 17,764,331 $40,142,172 -$4,573,760 $2.26 87
2022 Q4 19,144,470 $66,816,077 -$456,735,123 $3.49 106
2022 Q3 25,783,847 $954,470,507 +$46,796,895 $37.02 131
2022 Q2 24,632,853 $467,785,642 +$33,496,825 $18.99 106
2022 Q1 23,069,358 $622,305,579 +$69,498,228 $26.99 107
2021 Q4 20,739,885 $467,189,248 +$239,138,409 $22.53 91
2021 Q3 10,023,314 $262,675,920 -$4,620,967 $26.21 81
2021 Q2 9,944,006 $318,306,821 +$11,580,961 $32.01 83
2021 Q1 9,536,264 $335,739,251 +$3,534,612 $35.21 81
2020 Q4 9,311,019 $298,677,225 -$48,362,964 $32.07 79
2020 Q3 10,443,239 $392,874,164 -$4,538,306 $37.62 72
2020 Q2 10,506,228 $469,323,200 +$57,833,259 $44.75 74
2020 Q1 9,357,083 $319,169,853 +$94,707,648 $34.11 43
2019 Q4 6,797,480 $265,100,975 +$264,710,973 $39.00 44